Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary Sarcoidosis

Completed · Phase 2 · Has a placebo group

Conditions studied: Pulmonary Sarcoidosis

In brief

The purpose of this study is to assess if ACZ885 will improve lung function in association with reduction of tissue inflammation in patients with chronic sarcoidosis.

Key facts

Study ID

NCT02888080

Run by

Novartis Pharmaceuticals

People needed

40

Starts

2016-12-19

Expected to finish

2019-03-04

Last updated by the study team

2021-10-04

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Novartis Investigative Site — Birmingham, Alabama, United States
• Novartis Investigative Site — Albany, New York, United States
• Novartis Investigative Site — Cleveland, Ohio, United States
• Novartis Investigative Site — Essen, Germany
• Novartis Investigative Site — Frankfurt, Germany
• Novartis Investigative Site — Hanover, Germany
• Novartis Investigative Site — Nieuwegein, Netherlands
• Novartis Investigative Site — Rotterdam, Netherlands

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.